Post Profile






Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from a trial. The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo.
read more

share

Related Posts


Tesaro ovarian cancer drug shows broad benefits in study

Health : Reuters: Health

COPENHAGEN (Reuters) - Tesaro's experimental drug niraparib improved outcomes for a broad range of women with recurrent ovarian cancer in a clinical study, boosting prospects for the product, which belongs to a closely watched class...

BRCA-related breast and ovarian cancers showing early response to Investigational PARP inhibitor

Health : Medical News Today

An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented at the AAC...

Among Patients Carrying BRCA Mutations, PARP Inhibitor Shows Activity In Pancreatic, Prostate Cancers

Health : Medical News Today

In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancr...

Phase III Trial Of L-BLP25 In Patients With Non-Small Cell Lung Cancer (START) - Primary Endpoint Of Significantly Improving Overall Survival Not Met

Health : Medical News Today

Confirmed: Primary endpoint of significantly improving overall survival not met Merck Serono, a division of Merck, Darmstadt, Germany, today announced detailed results from the randomized Phase III START trial of its investigational...

Niraparib significantly improves outcome of ovarian cancer patients in landmark trial

Health : EurekAlert: Health

(European Society for Medical Oncology) The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first ti...

Comments


Copyright © 2016 Regator, LLC